Ring Therapeutics Announces Two Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Cambridge, Mass. – May 03, 2022 – Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its Anellogy^TM commensal virome platform, today announced two upcoming presentations at the 25^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held from May 16-19, 2022 in Washington, DC. These presentations further demonstrate the potential of Ring’s Anellogy^TM platform in harnessing the unique biology of anelloviruses to engineer the novel precision medicines.

Poster Presentations:

 

Title: Deep Immune Profiling of Candidate Endogenous Anellovirus Gene Therapy Vectors

Session Title: Immunological Aspects of Gene Therapy and Vaccines I

Abstract Number: 713

Board number: TU-218

Presenter: Harish Swaminathan

Presentation Date and Time: Tuesday, May 17, 2022, 5:30 – 6:30 p.m. ET

 

This poster presents data from a study that characterized the immunogenicity of anelloviruses and the antigenic profile of anellovirus proteins. Results showcase the favorable immune profile of anelloviruses.

Title: A novel gene delivery vector with low pre-existing immunity in humans 

Session Title: Vector Product Engineering, Development or Manufacturing III

Abstract Number: 1158

Board number: W-284

Presenter: Dhananjay Nawandar

Presentation Date and Time: Wednesday, May 18, 2022, 5:30 – 6:30 p.m. ET

Data in this poster show successful vectorization of synthetically produced anelloviruses to produce the first AnelloVector^TM therapeutic. These novel vectors can successfully target a variety of tissues, and no pre-existing immunity in humans is observed.